| 05/06/2026 10:00 AM | Arrowhead Pharmaceuticals (879407) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G | |
| 04/29/2026 3:44 PM | Arrowhead Pharmaceuticals (879407) Subject VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by | Form SCHEDULE 13G | |
| 04/28/2026 3:05 PM | Arrowhead Pharmaceuticals (879407) Subject VANGUARD PORTFOLIO MANAGEMENT LLC (2100121) Filed by | Form SCHEDULE 13G | |
| 04/24/2026 5:38 PM | Arrowhead Pharmaceuticals (879407) Issuer Hamilton James C (1830755) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/24/2026 5:44 PM | Apel Daniel Joseph (2081169) Reporting Arrowhead Pharmaceuticals (879407) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/23/2026 3:44 PM | Arrowhead Pharmaceuticals (879407) Subject Hamilton James C (1830755) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/22/2026 4:16 PM | Apel Daniel Joseph (2081169) Reporting Arrowhead Pharmaceuticals (879407) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/26/2026 2:43 PM | Arrowhead Pharmaceuticals (879407) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G/A | |
| 03/20/2026 3:05 PM | Arrowhead Pharmaceuticals (879407) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/09/2026 6:00 PM | Arrowhead Pharmaceuticals (879407) Issuer Hamilton James C (1830755) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/05/2026 3:49 PM | Arrowhead Pharmaceuticals (879407) Subject Hamilton James C (1830755) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for ARWR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
| 01/12/2026 4:00 PM | Arrowhead Pharmaceuticals (879407) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/08/2026 5:45 PM | Arrowhead Pharmaceuticals (879407) Issuer O'Brien Patrick (1627183) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/08/2026 5:45 PM | Apel Daniel Joseph (2081169) Reporting Arrowhead Pharmaceuticals (879407) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/08/2026 5:45 PM | Arrowhead Pharmaceuticals (879407) Issuer Hamilton James C (1830755) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/08/2026 4:05 PM | Arrowhead Pharmaceuticals (879407) Filer | Form 305B2 | |
| 01/07/2026 8:12 PM | Arrowhead Pharmaceuticals (879407) Subject | Form FWP | |
| 01/08/2026 5:12 AM | Arrowhead Pharmaceuticals (879407) Subject | Form FWP | |
| 01/06/2026 3:05 PM | Arrowhead Pharmaceuticals (879407) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/05/2026 8:50 PM | Arrowhead Pharmaceuticals (879407) Issuer O'Brien Patrick (1627183) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 8:39 PM | Anzalone Christopher Richard (1423029) Reporting Arrowhead Pharmaceuticals (879407) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 8:41 PM | Arrowhead Pharmaceuticals (879407) Issuer Hamilton James C (1830755) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 7:06 PM | Arrowhead Pharmaceuticals (879407) Subject Hamilton James C (1830755) Reporting | Form 144/A | |
| 01/05/2026 3:59 PM | Arrowhead Pharmaceuticals (879407) Subject Hamilton James C (1830755) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/02/2026 3:04 PM | Anzalone Christopher Richard (1423029) Reporting Arrowhead Pharmaceuticals (879407) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/30/2025 4:46 PM | Arrowhead Pharmaceuticals (879407) Issuer Ferrari Mauro (1506045) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/30/2025 4:46 PM | Anzalone Christopher Richard (1423029) Reporting Arrowhead Pharmaceuticals (879407) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 3:23 PM | Anzalone Christopher Richard (1423029) Reporting Arrowhead Pharmaceuticals (879407) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/23/2025 5:01 PM | Arrowhead Pharmaceuticals (879407) Issuer OLUKOTUN ADEOYE Y (1242615) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/23/2025 5:01 PM | Anzalone Christopher Richard (1423029) Reporting Arrowhead Pharmaceuticals (879407) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/23/2025 5:01 PM | Arrowhead Pharmaceuticals (879407) Issuer Vakiener Victoria (1826263) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/23/2025 5:01 PM | Arrowhead Pharmaceuticals (879407) Issuer Waddill William D. (1553338) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/19/2025 5:56 PM | Anzalone Christopher Richard (1423029) Reporting Arrowhead Pharmaceuticals (879407) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/19/2025 3:08 PM | Anzalone Christopher Richard (1423029) Reporting Arrowhead Pharmaceuticals (879407) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/19/2025 3:06 PM | Arrowhead Pharmaceuticals (879407) Subject Vakiener Victoria (1826263) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/19/2025 3:07 PM | Arrowhead Pharmaceuticals (879407) Subject OLUKOTUN ADEOYE Y (1242615) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/19/2025 3:07 PM | Arrowhead Pharmaceuticals (879407) Subject Waddill William D. (1553338) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/18/2025 5:39 PM | Arrowhead Pharmaceuticals (879407) Issuer OLUKOTUN ADEOYE Y (1242615) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 5:39 PM | Arrowhead Pharmaceuticals (879407) Issuer INGRAM DOUGLAS S (1190644) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 5:40 PM | Arrowhead Pharmaceuticals (879407) Issuer Vakiener Victoria (1826263) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 5:40 PM | Arrowhead Pharmaceuticals (879407) Issuer PERRY MICHAEL S (1250379) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
|
| 12/18/2025 5:40 PM | Arrowhead Pharmaceuticals (879407) Issuer Lu Hongbo (1767584) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 5:40 PM | Arrowhead Pharmaceuticals (879407) Issuer Ferrari Mauro (1506045) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 5:35 PM | Arrowhead Pharmaceuticals (879407) Issuer Waddill William D. (1553338) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/17/2025 4:11 PM | Anzalone Christopher Richard (1423029) Reporting Arrowhead Pharmaceuticals (879407) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/16/2025 3:47 PM | Anzalone Christopher Richard (1423029) Reporting Arrowhead Pharmaceuticals (879407) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/16/2025 12:14 PM | Anzalone Christopher Richard (1423029) Reporting Arrowhead Pharmaceuticals (879407) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/15/2025 3:50 PM | Anzalone Christopher Richard (1423029) Reporting Arrowhead Pharmaceuticals (879407) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/10/2025 8:54 PM | Arrowhead Pharmaceuticals (879407) Filer | Form S-3ASR | |
| 12/09/2025 5:04 PM | Arrowhead Pharmaceuticals (879407) Issuer PERRY MICHAEL S (1250379) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/01/2025 5:10 PM | Arrowhead Pharmaceuticals (879407) Issuer Ferrari Mauro (1506045) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/28/2025 12:19 PM | Arrowhead Pharmaceuticals (879407) Subject Ferrari Mauro (1506045) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/25/2025 3:10 PM | Arrowhead Pharmaceuticals (879407) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/25/2025 3:13 PM | Arrowhead Pharmaceuticals (879407) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 11/18/2025 1:49 PM | Arrowhead Pharmaceuticals (879407) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/10/2025 3:02 PM | Arrowhead Pharmaceuticals (879407) Filer | Form 10-K/A | |
| 10/03/2025 5:15 PM | Arrowhead Pharmaceuticals (879407) Issuer Hamilton James C (1830755) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/01/2025 2:44 PM | Arrowhead Pharmaceuticals (879407) Subject Hamilton James C (1830755) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/16/2025 5:06 PM | Arrowhead Pharmaceuticals (879407) Issuer Hamilton James C (1830755) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/12/2025 3:33 PM | Arrowhead Pharmaceuticals (879407) Subject Hamilton James C (1830755) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/11/2025 6:31 AM | Arrowhead Pharmaceuticals (879407) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/04/2025 4:37 PM | Arrowhead Pharmaceuticals (879407) Issuer Hamilton James C (1830755) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/02/2025 4:12 PM | Arrowhead Pharmaceuticals (879407) Subject Hamilton James C (1830755) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/15/2025 4:59 PM | Arrowhead Pharmaceuticals (879407) Issuer Hamilton James C (1830755) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/15/2025 4:28 PM | Arrowhead Pharmaceuticals (879407) Subject Sarepta Therapeutics, Inc. (873303) Filed by | Form SCHEDULE 13D/A | |
| 08/15/2025 2:42 PM | Arrowhead Pharmaceuticals (879407) Subject Hamilton James C (1830755) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/14/2025 6:07 AM | Arrowhead Pharmaceuticals (879407) Subject Avoro Capital Advisors LLC (1633313) Filed by | Form SCHEDULE 13G/A | |
| 08/13/2025 7:55 PM | Arrowhead Pharmaceuticals (879407) Subject Sarepta Therapeutics, Inc. (873303) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2025 4:57 PM | Arrowhead Pharmaceuticals (879407) Subject Hamilton James C (1830755) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/12/2025 4:49 PM | Apel Daniel Joseph (2081169) Reporting Arrowhead Pharmaceuticals (879407) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 08/11/2025 6:01 AM | Arrowhead Pharmaceuticals (879407) Subject STATE STREET CORP (93751) Filed by STATE STREET CORP (93751) Filed by | Form SCHEDULE 13G | |
| 07/29/2025 10:20 AM | Arrowhead Pharmaceuticals (879407) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G/A | |
| 07/10/2025 3:30 PM | Arrowhead Pharmaceuticals (879407) Subject Myszkowski Kenneth Allen (1486672) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/13/2025 9:26 AM | Arrowhead Pharmaceuticals (879407) Subject STATE STREET CORP (93751) Filed by STATE STREET CORP (93751) Filed by | Form SCHEDULE 13G | |